Why orals are a different risk category
Oral anabolic steroids are made orally active by a structural modification — 17-alpha-alkylation — that lets them survive first-pass metabolism in the liver. That same modification is precisely what makes them harder on the body. The property that gets the drug into your bloodwork intact is the property that stresses your liver and wrecks your lipids. This is why orals sit in a different risk category from injectable testosterone, and why they are the compounds this course treats with the most caution.
The lipid hit is fast, large, and well-documented
This is among the best-established facts in anabolic pharmacology. Oral 17-alpha-alkylated compounds sharply suppress HDL and raise LDL — and they do it within weeks, even at modest doses. The contrast with injectables is stark: LDL is generally little affected by injectable testosterone even at higher doses, while oral compounds consistently push it the wrong way. Because LDL and HDL move, the atherogenic particle burden — best captured by ApoB — rises (direct ApoB data on cycles is thinner than the HDL/LDL data, but the direction is not in doubt). A dyslipidemic panel during an oral cycle is expected, which is exactly why ApoB is the marker to watch: a sustained high ApoB that doesn't recover off-cycle is a real cardiovascular cost, not an acceptable price of admission.
The liver hit, and how to read it
17-alpha-alkylated orals are hepatotoxic — they raise ALT, AST, and GGT, and at the extreme can cause cholestasis and genuine liver injury. The interpretation trap from the Bloodwork course applies hard here: AST and ALT also rise from training and muscle, so the tiebreaker is GGT (the most liver-specific of the three) and bilirubin. A transaminase bump with a clean GGT may be muscle; a rising GGT alongside the transaminases, or a climbing bilirubin, is the liver genuinely struggling — and symptoms (dark urine, right-upper-quadrant pain, jaundice) override everything. Some enzyme elevation during an oral cycle is expected; a sustained or climbing trend is the signal to stop.
Harm reduction for orals
If orals are used at all, the discipline is built around their specific costs: minimize duration (the damage is dose-and-time dependent, so short, defined runs beat extended use), monitor ApoB and the liver panel on and off cycle, and use the dietary levers from the Dieting course — soluble fiber, marine omega-3, a shift away from saturated fat — which are a partial but real counter to the lipid hit. None of this makes orals "safe"; it makes the cost visible and bounded instead of silent and open-ended. The athlete who runs an oral for twelve weeks without pulling a lipid or liver panel has no idea what it cost them — and that ignorance is the actual danger.
The honest bottom line
Injectable testosterone, well-monitored, is a manageable long-term proposition for many. Oral 17-alpha-alkylated compounds are not in the same conversation — they extract a faster, larger toll on the two organ systems (cardiovascular and hepatic) that determine long-term survival. Treat them as short-term, tightly-monitored tools at most, and read ApoB and GGT as the honest scorecard of what they're costing you.
Educational content, not individual medical advice.